A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma (TRI Pro)
Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig, compared to participants who receive placebo. CRS is an acute inflammatory reaction that can occur during treatment and may be associated with flu-like or other systemic symptoms, such as fever and tiredness.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Study Contact
- 电话号码:844-434-4210
- 邮箱:Participate-In-This-Study1@its.jnj.com
学习地点
-
-
-
Budapest、匈牙利、1088
- 招聘中
- Semmelweis Egyetem
-
Budapest、匈牙利、1097
- 招聘中
- Del Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet Szent Laszlo Telephely
-
Budapest、匈牙利、1122
- 招聘中
- Orszagos Onkologiai Intezet
-
Pécs、匈牙利、7624
- 招聘中
- Pecsi Tudomanyegyetem Klinikai Kozpont
-
Szeged、匈牙利、6725
- 招聘中
- Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar
-
-
-
-
-
Alexandroupoli、希腊、681 00
- 招聘中
- Uni General Hospital of Alexandroupolis
-
Athens、希腊、11528
- 招聘中
- Alexandra General Hospital of Athens
-
Athens、希腊、115 25
- 招聘中
- 251 Air Force General Hospital
-
Piraeus、希腊、18537
- 招聘中
- Metaxa Cancer Center Hospital Of Piraeus
-
Rio、希腊、265 04
- 招聘中
- General University Hospital of Patras
-
Thessaloniki、希腊、54642
- 招聘中
- Hippokration Hospital
-
Thessaloniki、希腊、546 39
- 招聘中
- Theageneio Cancer Hospital
-
-
-
-
-
Argenteuil、法国、95107
- 招聘中
- Centre Hospitalier Victor Dupouy
-
Bayonne、法国、64100
- 招聘中
- Centre Hospitalier de la Cote Basque
-
La Tronche、法国、38700
- 招聘中
- CHU de Grenoble
-
Le Mans、法国、72100
- 招聘中
- Centre de Cancerologie de la Sarthe
-
Nantes、法国、44000
- 招聘中
- CHU Nantes - Hotel Dieu
-
Quimper、法国、29000
- 招聘中
- Centre Hospitalier de Quimper Cornouaille
-
-
-
-
-
Bedford Park、澳大利亚、5042
- 招聘中
- Flinders Medical Centre
-
Birtinya、澳大利亚、4575
- 招聘中
- Sunshine Coast University Hospital
-
Concord、澳大利亚、2139
- 招聘中
- Concord Repatriation General Hospital
-
Fitzroy、澳大利亚、3065
- 招聘中
- St Vincents Hospital Melbourne
-
Wollongong、澳大利亚、2500
- 招聘中
- Wollongong Hospital
-
-
-
-
-
Falun、瑞典、791 82
- 招聘中
- Falu Lasarett Medicinkliniken Falun
-
Gothenburg、瑞典、413 45
- 招聘中
- Sahlgrenska Universitetssjukhuset
-
Lund、瑞典、221 85
- 招聘中
- Skanes universitetssjukhus
-
Stockholm、瑞典、141 86
- 招聘中
- Karolinska University Hospital Huddinge
-
Uppsala、瑞典、752 37
- 招聘中
- Akademiska Sjukhuset
-
-
-
-
Arizona
-
Goodyear、Arizona、美国、85338
- 招聘中
- City of Hope Phoenix
-
-
California
-
Beverly Hills、California、美国、90211
- 招聘中
- Beverly Hills Cancer Center (BHCC)
-
Irvine、California、美国、92618
- 招聘中
- City of Hope Orange County Lennar Foundation Cancer Center
-
Palo Alto、California、美国、94304
- 招聘中
- Stanford University Medical Center
-
-
Colorado
-
Denver、Colorado、美国、80218
- 招聘中
- Colorado Blood Cancer Institute
-
-
Missouri
-
St Louis、Missouri、美国、63110
- 招聘中
- Washington University School Of Medicine
-
-
Ohio
-
Columbus、Ohio、美国、43214
- 招聘中
- Ohio Health Research Institute
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- 招聘中
- Sarah Cannon Research Institute
-
-
Utah
-
Salt Lake City、Utah、美国、84112
- 招聘中
- University of Utah Huntsman Cancer Institute
-
-
-
-
-
Braga、葡萄牙、4710 243
- 招聘中
- Uls Braga - Hosp. Braga
-
Lisbon、葡萄牙、1099 023
- 招聘中
- Ipo Lisboa
-
Lisbon、葡萄牙、1998 018
- 招聘中
- Hosp. Cuf Descobertas
-
Porto、葡萄牙、4200 319
- 招聘中
- Uls Sao Joao - Hosp. Sao Joao
-
Porto、葡萄牙、4050 342
- 招聘中
- Uls Santo Antonio - Hosp. Santo Antonio
-
Vila Nova de Gaia、葡萄牙、4434 502
- 招聘中
- Uls Gaia Espinho
-
-
-
-
-
Barcelona、西班牙、08041
- 招聘中
- Hosp. de La Santa Creu I Sant Pau
-
León、西班牙、24071
- 招聘中
- Hosp. de Leon
-
Madrid、西班牙、28046
- 招聘中
- Hosp. Univ. La Paz
-
Madrid、西班牙、28055
- 招聘中
- Hosp. Blua Sanitas Valdebebas
-
Málaga、西班牙、29010
- 招聘中
- Hosp Regional Univ de Malaga
-
Pamplona、西班牙、31008
- 招聘中
- Hosp. de Navarra
-
Valencia、西班牙、46017
- 招聘中
- Hosp. Univ. Dr. Peset
-
-
-
-
-
Buenos Aires、阿根廷、C1199ABB
- 招聘中
- Hospital Italiano de Buenos Aires
-
Buenos Aires、阿根廷、C1426ANZ
- 招聘中
- Instituto Alexander Fleming
-
Buenos Aires、阿根廷、C1118
- 招聘中
- Hospital Aleman
-
Córdoba、阿根廷、X5016KEH
- 招聘中
- Hospital Privado Centro Medico de Cordoba
-
Pilar、阿根廷、1629
- 招聘中
- Hospital Universitario Austral
-
-
-
-
-
Ampang、马来西亚、68000
- 招聘中
- Hospital Ampang
-
George Town、马来西亚、10450
- 招聘中
- Hospital Pulau Pinang
-
Johor Bharu、马来西亚、80100
- 招聘中
- Hospital Sultanah Aminah
-
Kota Kinabalu、马来西亚、88586
- 招聘中
- Hospital Queen Elizabeth
-
Kuching、马来西亚、93586
- 招聘中
- Sarawak General Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion criteria:
- Documented diagnosis of multiple myeloma (MM) as defined by the criteria: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria; b. Measurable disease at screening as assessed by local laboratory as defined in the protocol
- Received at least 1 prior lines of antimyeloma therapy
- Relapsed or refractory disease as defined: a. Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease (PD) by the IMWG response criteria greater than (>) 60 days after cessation of treatment.; b. Refractory disease is defined as failure to achieve a response or confirmed PD by the IMWG response criteria during previous treatment or less than or equal to (<=) 60 days after cessation of treatment
- Have an eastern cooperative oncology group (ECOG) performance status (PS) score of 0 to 2 at screening and immediately before the start of study treatment administration. Participants with ECOG PS 2 or 3 are eligible for the study if the ECOG PS score is related to stable physical limitations (example, wheelchair-bound due to prior spinal cord injury) and not related to MM or associated therapy
- Have clinical laboratory values meeting the criteria specified in the protocol
Exclusion criteria:
- Concurrent use of any other anticancer treatment (including non-palliative radiotherapy) or investigational agent
- Major surgery, (for example, requiring general anesthesia) within 2 weeks before first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study
- Suspected or known allergies, hypersensitivity, or intolerance to ramantamig and tocilizumab or their excipients
- Presence of any of the following: a. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); b. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; c. Any active malignancy other than MM
- Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm A: Tocilizumab + Ramantamig
Participants will receive tocilizumab along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until progressive disease (PD) or intolerable toxicity (whichever is earlier). |
Ramantamig will be administered as subcutaneous (SC) injection.
其他名称:
Tocilizumab will be administered as intravenous (IV) injection. |
|
安慰剂比较:Arm B: Placebo + Ramantamig
Participants will receive placebo (saline) along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until PD or intolerable toxicity (whichever is earlier). |
Ramantamig will be administered as subcutaneous (SC) injection.
其他名称:
Placebo (saline) will be administered as IV injection. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants Alive and Free of Treatment-Emergent American Society for Transplantation and Cellular Therapy (ASTCT) Grade Greater Than or Equal to (>=) 2 Cytokine Release Syndrome (CRS)
大体时间:By the end of Day 28 from first ramantamig dose
|
Percentage of participants alive and free of treatment-emergent ASTCT Grade >=2 CRS without the use of intervening treatment for CRS of any grade by the end of day 28 from first ramantamig dose will be reported. |
By the end of Day 28 from first ramantamig dose
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the End of Day 28 from First Ramantamig Dose
大体时间:By the end of Day 28 from first ramantamig dose
|
Percentage of participants with treatment-emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the end of day 28 from first ramantamig dose, respectively, will be reported. |
By the end of Day 28 from first ramantamig dose
|
|
Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 During Ramantamig Treatment
大体时间:Up to 38 months
|
Percentage of participants with treatment-emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 during ramantamig treatment will be reported. |
Up to 38 months
|
|
Percentage of Participants with Re-occurrence of CRS with ASTCT Grade >=2 After the Initial Occurrence of Treatment-Emergent Grade >=2 CRS Event
大体时间:Up to 38 months
|
Percentage of participants with re-occurrence of CRS with ASTCT Grade >=2 after the initial occurrence of treatment-emergent Grade >=2 CRS event will be reported. |
Up to 38 months
|
|
Percentage of Participants with Re-occurrence of CRS for All Grades
大体时间:Up to 38 months
|
Percentage of participants with re-occurrence of CRS for all Grades will be reported. |
Up to 38 months
|
|
Overall Response
大体时间:Up to 38 months
|
Overall response is defined as the percentage of participants who achieve partial response (PR) or better prior to progressive disease (PD) or subsequent antimyeloma therapy, in accordance with the international myeloma working group (IMWG) criteria. |
Up to 38 months
|
|
Complete Response (CR) or Better
大体时间:Up to 38 months
|
CR or better rate is defined as the percentage of participants achieving CR or stringent complete response (sCR) prior to PD or subsequent antimyeloma therapy, in accordance with the IMWG criteria. |
Up to 38 months
|
|
Very Good Partial Response (VGPR) or Better
大体时间:Up to Month 38
|
VGPR or better rate is defined as the percentage of participants achieving VGPR, CR or sCR prior to PD or subsequent antimyeloma therapy, in accordance with the IMWG criteria. |
Up to Month 38
|
|
Duration of Response (DoR)
大体时间:Up to 38 months
|
DoR is defined as the time interval between the date of initial documentation of a response (PR or better) to the date of first documented evidence of PD according to the IMWG response criteria or death due to any cause, whichever occurs first. |
Up to 38 months
|
|
Time to Response (TTR)
大体时间:Up to 38 months
|
TTR is defined as the time from the date of randomization to the date of first documentation of a confirmed response (PR or better) for participants who have PR or better as their best response. |
Up to 38 months
|
|
Progression-Free Survival (PFS)
大体时间:Up to Month 38
|
PFS is defined as the duration from the date of randomization to either PD or death, whichever comes first. Disease progression will be determined according to the IMWG response criteria. |
Up to Month 38
|
|
Time to Subsequent Antimyeloma Therapy
大体时间:Up to Month 38
|
Time to subsequent antimyeloma therapy is defined as the time from randomization to the start of subsequent antimyeloma treatment. Death due to progressive disease without the start of any subsequent antimyeloma therapy will be considered as an event. |
Up to Month 38
|
|
Percentage of Participants With Treatment-Emergent Adverse Event (TEAE) by Severity
大体时间:Up to 38 months
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. Any new or worsening AE occurring at or after the initial administration of study treatment through the day of last dose plus 30 days or prior to the start of subsequent antimyeloma therapy, whichever is earlier, or any follow-up AE (linked to an existing TEAE) with onset date and time beyond 30 days after the last dose of study treatment but prior to the start of subsequent therapy, or any AE that is considered treatment-related regardless of the start date of the event, is considered to be treatment-emergent. TEAEs will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 6.0. Severity scale ranges from Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, Grade 5= death related to adverse event. |
Up to 38 months
|
|
Percentage of Participants with Abnormalities in Laboratory Parameters
大体时间:Up to 38 months
|
Percentage of participants with abnormalities in laboratory parameters (serum chemistry and hematology) will be reported. |
Up to 38 months
|
|
Percentage of Participants with Incidence of Adverse Events of Clinical Interests
大体时间:Up to 38 Months
|
Percentage of participants with incidence of adverse events of clinical interests such as cytopenia will be reported. |
Up to 38 Months
|
合作者和调查者
调查人员
- 研究主任:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 79635322MMY2002
- 2025-524793-42 (EudraCT编号)
- 2025 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.